CytoDyn Inc (OTCMKTS:CYDY) said Wednesday that data from the study of its monoclonal antibody treatment of HIV will be presented at a Seattle conference.
The biotech company said in a statement that the data will be presented at the Conference on Retroviruses and Opportunistic Infections on March 7.
The company’s leronlimab candidate is a once-weekly injection designed to block HIV-1 from entering and infecting human cells by binding to the CCR5 receptor, a protein on the surface of white blood cells that is related to the immune system. Read More
